PURPOSE OF REVIEW: Renal cell carcinoma (RCC) continues to be the subject of vigorous clinical and translational investigation.
Advances in systemic targeted therapies, new molecular pathways and immunotherapy approaches will be discussed.
RECENT FINDINGS: Agents targeting the vascular endothelial growth factor (VEGF) and/or the mammalian target of rapamycin (mTOR) pathways continue to be the mainstay for treating metastatic RCC (mRCC). Although enhanced target specificity has improved the toxicity profile associated with newer VEGF-pathway antagonists, durable complete responses remain the exception. Identification of novel pathways/agents, as well as the optimal sequencing and combination of existing targeted agents, remain areas of active study. In addition, emerging data from early clinical trials have reinvigorated interest in immunomodulatory agents.
SUMMARY: The therapeutic armamentarium available to genitourinary oncologists continues to grow, but much work remains to be done to fully realize the potential of pathway-specific targeted strategies and immune-based approaches for mRCC.
Written by:
Su D, Stamatakis L, Singer EA, Srinivasan R. Are you the author?
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Reference: Curr Opin Oncol. 2014 May;26(3):321-7.
doi: 10.1097/CCO.0000000000000069
PubMed Abstract
PMID: 24675233
UroToday.com Renal Cancer Section
